Form 4: Pacira CCO Sells Shares for Tax Obligations

Pacira BioSciences' Chief Commercial Officer, Brendan Teehan, disposed of 5,182 shares of common stock to cover tax withholding obligations related to a restricted stock unit award.

Summary

• Brendan Teehan, Chief Commercial Officer of Pacira BioSciences, Inc. (PCRX), reported a transaction on January 30, 2026.
• The transaction involved the disposition of 5,182 shares of common stock at a price of $20.54 per share.
• These shares were withheld by the issuer to cover tax withholding obligations upon the vesting of a restricted stock unit award.
• Following this transaction, Brendan Teehan beneficially owns 49,220.268 shares of Pacira BioSciences common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it reports a routine, non-discretionary transaction related to equity compensation and does not reflect a change in management's confidence or the company's operational performance.

Positives

• The underlying restricted stock unit award vested, indicating the achievement of performance or tenure milestones by the Chief Commercial Officer.

Negatives

• None directly indicated by this routine tax-related disposition.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing the disposition of shares for tax withholding purposes are a routine and common occurrence for executives receiving equity compensation, reflecting the mechanical process of managing vested restricted stock units.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction by an insider to cover tax liabilities, not a discretionary sale indicating a change in sentiment.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by an insider to cover tax obligations related to a restricted stock unit award. It does not provide new information that would alter the fundamental investment thesis for Pacira BioSciences, Inc., thus a 'hold' recommendation is appropriate.

Keywords

Pacira BioSciences, PCRX, Form 4, insider transaction, stock sale, tax withholding, restricted stock unit, Brendan Teehan